$82.6 Million is the total value of Ally Bridge Group (NY) LLC's 17 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 94.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RETA | New | REATA PHARMACEUTICALS INC-Acl a | $10,762,694 | – | 105,558 | +100.0% | 13.04% | – |
| VRNA | VERONA PHARMA PLC - ADRsponsored ads | $10,308,519 | +5.3% | 487,631 | 0.0% | 12.49% | -2.7% | |
| XENE | XENON PHARMACEUTICALS INC | $10,277,999 | +7.6% | 266,961 | 0.0% | 12.45% | -0.6% | |
| CYTK | CYTOKINETICS INC | $7,286,721 | -7.3% | 223,382 | 0.0% | 8.83% | -14.3% | |
| GERN | New | GERON CORP | $6,815,350 | – | 2,123,162 | +100.0% | 8.26% | – |
| MRUS | Sell | MERUS NV | $5,245,489 | +3.3% | 199,221 | -27.8% | 6.35% | -4.6% |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $4,799,680 | – | 201,752 | +100.0% | 5.81% | – |
| Buy | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $4,662,063 | +199.2% | 91,413 | +25.5% | 5.65% | +176.4% | |
| New | MARINUS PHARMACEUTICALS INC | $4,239,939 | – | 390,418 | +100.0% | 5.14% | – | |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $4,040,000 | – | 800,000 | +100.0% | 4.89% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $3,680,000 | – | 3,200,000 | +100.0% | 4.46% | – |
| JASPER THERAPEUTICS INC | $3,448,608 | -24.3% | 2,517,232 | 0.0% | 4.18% | -30.1% | ||
| CMPX | New | COMPASS THERAPEUTICS INC | $2,908,523 | – | 914,630 | +100.0% | 3.52% | – |
| MDVL | MEDAVAIL HOLDINGS INC | $1,444,839 | -14.5% | 5,894,897 | 0.0% | 1.75% | -21.0% | |
| Sell | MDXHEALTH SA-ADRsponsored ads | $1,191,972 | -26.4% | 349,552 | -30.1% | 1.44% | -32.0% | |
| New | CONTEXT THERAPEUTICS INC | $1,045,434 | – | 653,396 | +100.0% | 1.27% | – | |
| Sell | RAPID MICRO BIOSYSTEMS INC-A | $403,284 | -56.0% | 403,284 | -42.4% | 0.49% | -59.4% | |
| Exit | SYROS PHARMACEUTICALS INC | $0 | – | -249,126 | -100.0% | -0.87% | – | |
| KNTE | Exit | KINNATE BIOPHARMA INC | $0 | – | -109,393 | -100.0% | -0.90% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -236,583 | -100.0% | -0.92% | – |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -550,000 | -100.0% | -3.03% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -20,830 | -100.0% | -3.76% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -1,191,271 | -100.0% | -6.42% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -255,310 | -100.0% | -8.14% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -29,614 | -100.0% | -9.40% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -1,131,827 | -100.0% | -10.68% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.